title: Single-shot, high-dose rabbit ATG for rejection prophylaxis after kidney transplantation.
abstract: We studied the effects of a single intravenous injection of rabbit ATG (RIVM, Bilthoven, The Netherlands) in a dose of 8 mg/kg body weight administered 6 h after kidney transplantation on graft survival, rejection incidence, T-cell subsets, and cost-effectiveness. A total of 58 (37 male/21 female) consecutive renal allograft recipients were entered in this trial. Treatment results were compared with 56 patients treated with intravenous cyclosporin (CyA). In all patients concomitant medication consisted of steroids and azathioprine, followed by oral CyA. Following rabbit ATG, T cells (WT31) quickly disappeared from the peripheral blood and a return to greater than 100/mm3 was observed at a median of 7 (range 3-21) days. Graft survival was the same in both groups, as was the incidence of primary nonfunction. The rate of acute rejection was significantly lower in the rabbit ATG-treated patients (12% vs 50%). We conclude that a single shot of rabbit ATG is an attractive, easy, and cost-effective induction scheme with a low incidence of delayed graft function and acute rejection episodes. A relatively high incidence of vascular thrombosis of the graft, however, warrants further study before this treatment regimen can be generally applied.
authors.affiliation: Department of Internal Medicine I, University Hospital Dijkzigt, Rotterdam, The Netherlands.
authors.forename: R
authors.initials: R
authors.lastname: Zietse
authors.forename: E P
authors.initials: EP
authors.lastname: van Steenberge
authors.forename: C J
authors.initials: CJ
authors.lastname: Hesse
authors.forename: L B
authors.initials: LB
authors.lastname: Vaessen
authors.forename: J N
authors.initials: JN
authors.lastname: IJzermans
authors.forename: W
authors.initials: W
authors.lastname: Weimar
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D000961:Antilymphocyte Serum / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006084:Graft Rejection / Q000276:immunology / Q000628:therapy*; D006085:Graft Survival; D006801:Humans; D007167:Immunotherapy; D015994:Incidence; D007275:Injections, Intravenous; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011292:Premedication; D011817:Rabbits; D013601:T-Lymphocytes / Q000276:immunology*; D014184:Transplantation, Homologous
chemical_list: D000961:Antilymphocyte Serum